Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Leukemia

Free Subscription Articles published in Cancer Retrieve available abstracts of 102 articles: HTML format Text format

Single Articles

February 2012
1. STROM SS , Oum R, Elhor Gbito KY, Garcia-Manero G, et al
   De novo acute myeloid leukemia risk factors: A Texas case-control study.
   Cancer. 2012 Feb 1. doi: 10.1002/cncr.27442.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   January 2012
2. HUANG X , Cortes J, Kantarjian H
   Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
   Cancer. 2012 Jan 31. doi: 10.1002/cncr.26679.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
3. FADERL S , Ravandi F, Huang X, Wang X, et al
   Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
   Cancer. 2012 Jan 26. doi: 10.1002/cncr.27429.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   December 2011
4. ABDULWAHAB A , Sykes J, Kamel-Reid S, Chang H, et al
   Therapy-related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis.
   Cancer. 2011 Dec 16. doi: 10.1002/cncr.26735.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. MONK JP , Halabi S, Picus J, Hussain A, et al
   Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: Results of Cancer and Leukemia Group B (CALGB) 9782.
   Cancer. 2011 Dec 16. doi: 10.1002/cncr.26732.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
6. SINGH MM , Irwin ME, Gao Y, Ban K, et al
   Inhibition of the NADPH oxidase regulates heme oxygenase 1 expression in chronic myeloid leukemia.
   Cancer. 2011 Dec 2. doi: 10.1002/cncr.26621.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. GARG R , Wierda W, Ferrajoli A, Abruzzo L, et al
   The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia.
   Cancer. 2011 Dec 2. doi: 10.1002/cncr.26593.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   October 2011
8. JABBOUR E , Saglio G, Hughes TP, Kantarjian H, et al
   Suboptimal responses in chronic myeloid leukemia: Implications and management strategies.
   Cancer. 2011 Oct 28. doi: 10.1002/cncr.26391.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   September 2011
9. FANG M , Storer B, Wood B, Gyurkocza B, et al
   Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation.
   Cancer. 2011 Sep 16. doi: 10.1002/cncr.26539.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
10. MEDEIROS BC , Othus M, Fang M, Appelbaum FR, et al
    Impact of residual normal metaphases in core binding factor acute myeloid leukemia.
    Cancer. 2011 Sep 16. doi: 10.1002/cncr.26557.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
11. LEE BN , Gao H, Cohen EN, Badoux X, et al
    Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.
    Cancer. 2011;117:3999-4008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2011
12. MASOOD A , Sher T, Chanan-Khan A
    Reply to tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.
    Cancer. 2011 Aug 31. doi: 10.1002/cncr.26370.
    PubMed     Text format     Related articles   
    
    
    
    
13. SHANAFELT TD , Kay NE, Rabe KG, Inwards DJ, et al
    Hematologist/oncologist disease-specific expertise and survival: Lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
    Cancer. 2011 Aug 26. doi: 10.1002/cncr.26474.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
14. PINTO A , Corazzelli G, De Filippi R
    Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.
    Cancer. 2011 Jul 15. doi: 10.1002/cncr.26380.
    PubMed     Text format     Related articles   
    
    
    
    
15. NESS KK , Hudson MM, Pui CH, Green DM, et al
    Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia: Associations with physical performance and chemotherapy doses.
    Cancer. 2011 Jul 15. doi: 10.1002/cncr.26337.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
16. COOPER TM , Franklin J, Gerbing RB, Alonzo TA, et al
    AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the children's oncology group.
    Cancer. 2011 Jul 15. doi: 10.1002/cncr.26190.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
17. KOJIMA K , Duvvuri S, Ruvolo V, Samaniego F, et al
    Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.
    Cancer. 2011 Jul 14. doi: 10.1002/cncr.26360.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. MAURILLO L , Venditti A, Spagnoli A, Gaidano G, et al
    Azacitidine for the treatment of patients with acute myeloid leukemia : Report of 82 patients enrolled in an italian compassionate program.
    Cancer. 2011 Jul 14. doi: 10.1002/cncr.26354.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. CABANILLAS ME , Kantarjian H, Thomas DA, Mattiuzzi GN, et al
    Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: Results of a Randomized Clinical Trial.
    Cancer. 2011 Jul 12. doi: 10.1002/cncr.26341.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. NICOLINI FE , Turkina A, Shen ZX, Gallagher N, et al
    Expanding Nilotinib Access in Clinical Trials (ENACT): An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
    Cancer. 2011 Jul 5. doi: 10.1002/cncr.26249.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2011
21. CORTES J , Kantarjian H, Ball ED, Dipersio J, et al
    Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia.
    Cancer. 2011 Jun 29. doi: 10.1002/cncr.26292.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
22. ARELLANO M , Winton E, Pan L, Lima L, et al
    High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years.
    Cancer. 2011 Jun 29. doi: 10.1002/cncr.26290.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. RADICH JP
    Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.
    Cancer. 2011 Jun 29. doi: 10.1002/cncr.26280.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. VALCARCEL D , Montesinos P, Sanchez-Ortega I, Brunet S, et al
    A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia.
    Cancer. 2011 Jun 29. doi: 10.1002/cncr.26273.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
25. ROBERTS AS , Campa MJ, Gottlin EB, Jiang C, et al
    Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (cancer and leukemia group B 80303).
    Cancer. 2011 Jun 28. doi: 10.1002/cncr.26270.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
26. SHIHADEH F , Reed V, Faderl S, Medeiros LJ, et al
    Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease.
    Cancer. 2011 Jun 20. doi: 10.1002/cncr.26253.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. DING N , Yamashita U, Matsuoka H, Sugiura T, et al
    Apoptosis induction through proteasome inhibitory activity of cucurbitacin D in human T-cell leukemia.
    Cancer. 2011;117:2735-46.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. COSTA R , Abdulhaq H, Haq B, Shadduck RK, et al
    Activity of azacitidine in chronic myelomonocytic leukemia.
    Cancer. 2011;117:2690-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. MAMON HJ , Niedzwiecki D, Hollis D, Tan BR, et al
    A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : Cancer and Leukemia Group B (CALGB) 80003.
    Cancer. 2011;117:2620-2628.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
30. QUINTAS-CARDAMA A , Cortes JE, Kantarjian HM
    Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: Long-term implications.
    Cancer. 2011 May 19. doi: 10.1002/cncr.26196.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
31. ROWE JM , Kim HT, Tallman MS
    Reply to induction therapy and outcome in acute myeloid leukemia.
    Cancer. 2011;117:2237.
    PubMed     Text format     Related articles   
    
    
    
    
32. MEHTA J
    Induction therapy and outcome in acute myeloid leukemia.
    Cancer. 2011;117:2236-7.
    PubMed     Text format     Related articles   
    
    
    
    
33. WEISS L , Melchardt T, Egle A, Grabmer C, et al
    Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia.
    Cancer. 2011;117:2163-9.
    PubMed     Text format     Related articles   
    
    
    
    
34. TIRIBELLI M , Geromin A, Michelutti A, Cavallin M, et al
    Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse.
    Cancer. 2011;117:2156-62.
    PubMed     Text format     Related articles   
    
    
    
    
35. SANTOS FP , Jones D, Qiao W, Cortes JE, et al
    Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.
    Cancer. 2011;117:2145-55.
    PubMed     Text format     Related articles   
    
    
    
    
36. CHANAN-KHAN A , Miller KC, Lawrence D, Padmanabhan S, et al
    Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.
    Cancer. 2011;117:2127-35.
    PubMed     Text format     Related articles   
    
    
    
    
37. GUIDETTI A , Carlo-Stella C, Ruella M, Miceli R, et al
    Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.
    Cancer. 2011 May 12. doi: 10.1002/cncr.26182.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
38. BINDER M , Muller F, Jackst A, Lechenne B, et al
    B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia.
    Cancer. 2011;117:1891-900.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. JABBOUR E , Branford S, Saglio G, Jones D, et al
    Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
    Cancer. 2011;117:1800-11.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2011
40. QUINTAS-CARDAMA A , Kantarjian H, Shan J, Jabbour E, et al
    Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.
    Cancer. 2011 Apr 26. doi: 10.1002/cncr.26147.
    PubMed     Text format     Related articles   
    
    
    
    
41. LEE HJ , Thompson JE, Wang ES, Wetzler M, et al
    Philadelphia chromosome-positive acute lymphoblastic leukemia: Current treatment and future perspectives.
    Cancer. 2011;117:1583-94.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
42. FRIESE CR , Earle CC, Magazu LS, Brown JR, et al
    Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia.
    Cancer. 2011;117:1470-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
43. BELLO C , Yu D, Komrokji RS, Zhu W, et al
    Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.
    Cancer. 2011;117:1463-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
44. WETZLER M , Andrews C, Ford LA, Tighe S, et al
    Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia.
    Cancer. 2011 Mar 31. doi: 10.1002/cncr.26097.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
45. KONOPLEV S , Jorgensen JL, Thomas DA, Lin E, et al
    Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia.
    Cancer. 2011 Mar 31. doi: 10.1002/cncr.26113.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
46. KHOURI IF , Bassett R, Poindexter N, O'Brien S, et al
    Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: Long-Term Follow-Up, Prognostic Factors, and Effect of Human Leukocyte Histocompatibility Antigen Subtype on Outcome.
    Cancer. 2011 Mar 31. doi: 10.1002/cncr.26091.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. BRADLEY CJ , Dahman B, Jin Y, Shickle LM, et al
    Acute myeloid leukemia: How the Uninsured Fare.
    Cancer. 2011 Mar 31. doi: 10.1002/cncr.26095.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
48. HAVELANGE V , Stauffer N, Heaphy CC, Volinia S, et al
    Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling.
    Cancer. 2011 Mar 31. doi: 10.1002/cncr.26096.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
49. GUPTA S , Antillon FA, Bonilla M, Fu L, et al
    Treatment-related mortality in children with acute lymphoblastic leukemia in Central America.
    Cancer. 2011 Mar 28. doi: 10.1002/cncr.26107.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
50. CERVANTES F , Mauro M
    Practical management of patients with chronic myeloid leukemia.
    Cancer. 2011 Mar 16. doi: 10.1002/cncr.26062.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
51. INABA H , Cao X, Pounds S, Pui CH, et al
    Randomized trial of 2 dosages of prophylactic granulocyte-colony-stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia.
    Cancer. 2011;117:1313-20.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
52. LIMA L , Bernal-Mizrachi L, Saxe D, Mann KP, et al
    Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond.
    Cancer. 2011;117:1245-52.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
53. JULIUSSON G , Karlsson K, Lazarevic VL, Wahlin A, et al
    Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: Real-World Population-Based Data From the Swedish Acute Leukemia Registry 1997-2006.
    Cancer. 2011 Mar 8. doi: 10.1002/cncr.26033.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
54. JASO J , Thomas DA, Cunningham K, Jorgensen JL, et al
    Prognostic significance of immunophenotypic and karyotypic features of philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors.
    Cancer. 2011 Mar 1. doi: 10.1002/cncr.25978.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
55. PEMMARAJU N , Kantarjian H, Ravandi F, Cortes J, et al
    FLT3 inhibitors in the treatment of acute myeloid leukemia: The start of an era?
    Cancer. 2011 Feb 11. doi: 10.1002/cncr.25908.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
56. FERRARA F , Musto P
    Hypomethylating agents for the treatment of acute myeloid leukemia in the elderly: For all, none, or which patients?
    Cancer. 2011 Feb 1. doi: 10.1002/cncr.25934.
    PubMed     Text format     Related articles   
    
    
    
    January 2011
57. FERRAJOLI A , Keating MJ, O'Brien S, Cortes J, et al
    Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia.
    Cancer. 2011 Jan 18. doi: 10.1002/cncr.25853.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
58. TEFFERI A
    Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia: Before or after imatinib?
    Cancer. 2011;117:234-7.
    PubMed     Text format     Related articles   
    
    
    
    December 2010
59. DING N , Yamashita U, Matsuoka H, Sugiura T, et al
    Apoptosis induction through proteasome inhibitory activity of cucurbitacin D in human T-Cell leukemia.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
60. MAMON HJ , Niedzwiecki D, Hollis D, Tan BR, et al
    A phase 2 trial of gemcitabine, 5-florouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
61. COSTA R , Abdulhaq H, Haq B, Shadduck RK, et al
    Activity of azacitidine in chronic myelomonocytic leukemia.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
62. MATTIUZZI GN , Cortes JE, Blamble DA, Bekele BN, et al
    Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.
    Cancer. 2010;116:5659-66.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
63. DEARDEN CE , Richards S, Else M, Catovsky D, et al
    A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2010
64. SANTOS FP , Jones D, Qiao W, Cortes JE, et al
    Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
65. CHANAN-KHAN A , Miller KC, Lawrence D, Padmanabhan S, et al
    Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
66. TIRIBELLI M , Geromin A, Michelutti A, Cavallin M, et al
    Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
67. JABBOUR E , Branford S, Saglio G, Jones D, et al
    Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
68. BINDER M , Muller F, Jackst A, Lechenne B, et al
    B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
69. ROWE JM , Kim HT, Tallman MS
    Reply to induction therapy and outcome in acute myeloid leukemia.
    Cancer. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
70. MEHTA J
    Induction therapy and outcome in acute myeloid leukemia.
    Cancer. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
71. WEISS L , Melchardt T, Egle A, Grabmer C, et al
    Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
72. FRIESE CR , Earle CC, Magazu LS, Brown JR, et al
    Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
73. INABA H , Cao X, Pounds S, Pui CH, et al
    Randomized trial of 2 dosages of prophylactic granulocyte-colony-stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
74. BELLO C , Yu D, Komrokji RS, Zhu W, et al
    Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
75. LEE HJ , Thompson JE, Wang ES, Wetzler M, et al
    Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
76. LIMA L , Bernal-Mizrachi L, Saxe D, Mann KP, et al
    Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
77. CHATENOUD L , Bertuccio P, Bosetti C, Levi F, et al
    Childhood cancer mortality in America, Asia, and Oceania, 1970 through 2007.
    Cancer. 2010;116:5063-74.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2010
78. TEFFERI A
    Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia: before or after imatinib?
    Cancer. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
79. CORTES J , Quintas-Cardama A, Kantarjian HM
    Monitoring molecular response in chronic myeloid leukemia.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
80. SEKERES MA , Maciejewski JP, Erba HP, Afable M, et al
    A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
81. JABBOUR E , Kantarjian H, Ravandi F, Garcia-Manero G, et al
    A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
82. SANTOS FP , Alvarado Y, Kantarjian H, Verma D, et al
    Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
83. PREBET T , Etienne A, Devillier R, Romeo E, et al
    Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
84. JABBOUR E , Cortes J, Kantarjian H
    Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
85. PINILLA-IBARZ J , Cortes J, Mauro MJ
    Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2010
86. CORTES J , Quintas-Cardama A, Jones D, Ravandi F, et al
    Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
87. PICUS J , Halabi S, Kelly WK, Vogelzang NJ, et al
    A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
88. RAVANDI F
    Reply to Evaluation of PML Immunofluorescence, flow cytometric immunophenotypic analysis, and reverse transcriptase polymerase chain reaction for PML/RARa for rapid diagnosis of acute promyelocytic leukemia.
    Cancer. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
89. VARMA N , Agarwal C, Varma S
    Evaluation of PML immunofluorescence, flow cytometric immunophenotypic analysis, and reverse transcriptase polymerase chain reaction for PML/RARa for rapid diagnosis of acute promyelocytic leukemia.
    Cancer. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
90. AL-KALI A , Kantarjian H, Shan J, Bassett R, et al
    Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
91. PIETERS R , Hunger SP, Boos J, Rizzari C, et al
    L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2010
92. WIERDA WG , Kipps TJ, Keating MJ, Brown JR, et al
    Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
93. KOREN-MICHOWITZ M , le Coutre P, Duyster J, Scheid C, et al
    Erratum: Activity and Tolerability of Nilotinib: A Retrospective Multicenter Analysis of Chronic Myeloid Leukemia Patients Who Are Imatinib Resistant or Intolerant.
    Cancer. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
94. DAYYANI F , Kantarjian H, O'Brien S, Pierce S, et al
    Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
95. KANTARJIAN HM , Thomas D, Ravandi F, Faderl S, et al
    Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
96. ZHANG J , Guo H, Zhang H, Wang H, et al
    Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene friend leukemia virus integration 1 gene.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
97. JABBOUR E , Garcia-Manero G, Batty N, Shan J, et al
    Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.
    Cancer. 2010;116:3830-4.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2010
98. DE LIMA M , Giralt S, Thall PF, de Padua Silva L, et al
    Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
99. GRUSCHKUS SK , Lairson D, Dunn JK, Risser J, et al
    Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
100. RYTTING M , Ravandi F, Estey E, Cortes J, et al
     Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study.
     Cancer. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
101. CORTES J , De Souza C, Ayala-Sanchez M, Bendit I, et al
     Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET).
     Cancer. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     May 2010
102. JOSHUA TV , Rizzo JD, Zhang MJ, Hari PN, et al
     Access to hematopoietic stem cell transplantation: effect of race and sex.
     Cancer. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: